November 18, 2016 - By Marie Mckinney · 0 Comments
Ricebran Technologies (NASDAQ:RIBT) institutional sentiment decreased to 0.71 in 2016 Q2. Its down -0.43, from 1.14 in 2016Q1. The ratio dropped, as 8 funds increased and started new equity positions, while 7 sold and trimmed holdings in Ricebran Technologies. The funds in our partner’s database now have: 1.12 million shares, down from 1.35 million shares in 2016Q1. Also, the number of funds holding Ricebran Technologies in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 5 Increased: 4 New Position: 4.
RiceBran Technologies is a human food ingredient, functional food ingredient, packaged functional food and animal nutrition company. The company has a market cap of $11.99 million. The Firm is focused on processing and marketing of nutrient dense products derived from raw rice, an underutilized by-product of the rice milling industry. It currently has negative earnings. The Firm has two operating divisions.
About 17,108 shares traded hands or 204.14% up from the average. RiceBran Technologies (NASDAQ:RIBT) has declined 23.45% since April 18, 2016 and is downtrending. It has underperformed by 27.88% the S&P500.
According to Zacks Investment Research, “RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. The Company’s target markets are human food and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. RiceBran Technologies, formerly known as NutraCea, is headquartered in Scottsdale, AZ.”
Sabby Management Llc holds 0.07% of its portfolio in RiceBran Technologies for 785,476 shares. Bard Associates Inc owns 60,875 shares or 0.05% of their US portfolio. Moreover, Twin Focus Capital Partners Llc has 0.02% invested in the company for 11,545 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 1,578 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 buy, and 0 selling transactions for $14,778 net activity.
RiceBran Technologies, incorporated on March 18, 1998, is a human food ingredient, functional food ingredient, packaged functional food and animal nutrition company. The Firm is focused on processing and marketing of nutrient dense products derived from raw rice, an underutilized by-product of the rice milling industry. The Firm has two operating divisions: USA and Brazil. The Company’s USA segment makes and distributes stabilized rice bran (SRB) (for human food ingredient and animal nutrition customers) and derivative products. The Company’s Brazil segment extracts crude rice bran oil (RBO) and defatted rice bran (DRB) from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products for horses, cows, swine, sheep and poultry and a range of human food and animal nutrition products.
More notable recent RiceBran Technologies (NASDAQ:RIBT) news were published by: Seekingalpha.com which released: “RiceBran Technologies’ (RIBT) CEO Robert Smith on Q3 2016 Results – Earnings …” on November 12, 2016, also Marketwatch.com with their article: “RiceBran Technologies” published on November 08, 2012, Seekingalpha.com published: “RiceBran Technologies: Profit From The Turnaround” on August 16, 2016. More interesting news about RiceBran Technologies (NASDAQ:RIBT) were released by: Prnewswire.com and their article: “RiceBran Technologies and Medicus Research Release Claims Substantiation …” published on March 02, 2015 as well as Businesswire.com‘s news article titled: “RiceBran Technologies Announces Preliminary Results of Vote at Annual …” with publication date: June 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney